Skip to main content
SpringerLink
Log in

Donepezil

Pharmacoeconomic Implications of Therapy

  • Adis Formulary Perspective
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Donepezil is a specific acetylcholinesterase inhibitor that can improve symptoms in patients withmild-to-moderate Alzheimer’s disease; cognitive function is maintained above baseline levels for up to 1 year and normal decline of cognitive function is slowed. The ability of the patient to perform daily activities and neuropsychiatric symptoms may also be improved by donepezil, but data are limited.

Donepezil is not expected to alter the underlying neurodegenerative process, and the response to the drug varies between individuals.

In the absence of validated instruments to measure quality of life, it is not clear how donepezil affects this parameter.

In a US survey of caregivers of patients with Alzheimer’s disease who were being cared for at home at the start of the 6-month study period, treatment with donepezil did not increase overall direct medical costs. The acquisition cost of the drug was balanced by reduced institutionalisation costs.

Economic analyses usingMarkov models from the US, UK and Canada suggest that donepezil initiated in the early stages of disease may be effectively cost neutral as a result of patients remaining in a nonsevere state of disease for a longer time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry 1997 May; 154 (5 Suppl.): 1–39

    Google Scholar 

  2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997 Oct 22–29; 278: 1363–71

    Article  Google Scholar 

  3. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer’s disease. Clin Ther 1997 Mar- Apr; 19: 330–45

    CAS  Google Scholar 

  4. Baldereschi M, Di Carlo A, Amaducci L. Epidemiology of dementias. Drugs Today 1998; 34 (9): 747–58

    PubMed  CAS  Google Scholar 

  5. Hendrie HC. Epidemiology of Alzheimer’s disease. Geriatrics 1997 Sep; 52 Suppl. 2: S4–8

    Google Scholar 

  6. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150 (6): 899–913

    Google Scholar 

  7. Molnar FJ, Dalziel WB. The pharmacoeconomics of dementia therapies: bringing the clinical, research and economic perspectives together. Drugs Aging 1997 Mar; 10: 219–33

    Article  PubMed  CAS  Google Scholar 

  8. Meek PD, McKeithan EK, Schumock GT. Economic considerations in Alzheimer’s disease. Pharmacotherapy 1998 Mar-Apr; 18 (2 Pt 2): 68S-73S

    CAS  Google Scholar 

  9. Ernst RL, Hay JW. The US economic and social costs of Alzheimer’s Disease revisited. Am J Public Health 1994 Aug; 84 (8): 1261–4

    Article  PubMed  CAS  Google Scholar 

  10. Gray A, Fenn P. Alzheimer’s disease: the burden of illness in England. Health Trend 1993; 25 (1): 31–7

    CAS  Google Scholar 

  11. GreenerM. Counting the cost of Alzheimer’s disease. Inpharma 1999 Mar 20; 204: 3–4

    Google Scholar 

  12. Hux MJ, O’Brien B, Iskedjian M, et al. Relation between severity of Alzheimer’s disease and costs of caring. Can Med Assoc J 1998 Sep 8; 159: 457–65

    Google Scholar 

  13. Souêtre E, Thwaites RMA, Yeardley HL. Economic impact of Alzheimer’s disease in the United Kingdom: cost of care and disease severity for non-institutionalised patients with Alzheimer’s disease. Br J Psychiatry 1999; 174: 51–5

    Article  PubMed  Google Scholar 

  14. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease. Arch Neurol 1997 Jun; 54: 687–93

    Article  PubMed  CAS  Google Scholar 

  15. Leon J, Cheng C-K, Neumann PJ. Alzheimer’s disease care: costs and potential savings. Health Aff 1998 Nov-Dec; 17: 206–16

    Article  CAS  Google Scholar 

  16. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer’s disease. Drugs Aging 1999 May; 14 (5): 359–73

    Article  PubMed  CAS  Google Scholar 

  17. Unni LK. Beyond tacrine: recently developed cholinesterase inhibitors for the treatment of Alzheimer’s disease. CNS Drugs 1998 Dec; 10 (6): 447–60

    Article  CAS  Google Scholar 

  18. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer’s disease. Lancet 1997 Jul 26; 350: 232–3

    Article  Google Scholar 

  19. Nordberg A, Svensson A-L. Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology. Drug Saf 1998 Dec; 19: 465–80

    Article  PubMed  CAS  Google Scholar 

  20. Schachter AS, Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer’s disease. CNS Drugs 1999 Apr; 11 (4): 281–8

    Article  Google Scholar 

  21. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997 Mar; 10: 234–9

    Article  CAS  Google Scholar 

  22. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in Alzheimer’s disease. Drugs Aging 1994; 4 (6): 510–40

    Article  PubMed  CAS  Google Scholar 

  23. Rogers SL, Friedhoff LT, Donepezil SG. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a multicentre, randomized, double-blind, placebocontrolled trial. Dementia 1996 Nov-Dec; 7: 293–303

    PubMed  CAS  Google Scholar 

  24. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15- week, double-blind, placebo-controlled study. Arch Intern Med 1998 May 11; 158: 1021–31

    Article  Google Scholar 

  25. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998 Jan; 50: 136–45

    Article  PubMed  CAS  Google Scholar 

  26. Rogers SL, Friedhoff LT. Long term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of US multicentre open label extension study. Eur Neuropsychopharmacol 1998 Feb; 8: 67–75

    Article  PubMed  CAS  Google Scholar 

  27. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998 Jan; 32: 70–7

    Article  PubMed  CAS  Google Scholar 

  28. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health System Pharm 1997 Dec 15; 54: 2805–10

    Google Scholar 

  29. Maslow K, Whitehouse P. Defining and measuring outcomes in Alzheimer disease research: conference findings. Alz Dis Assoc Disord 1997; 11 Suppl. 6: 186–95

    Google Scholar 

  30. Gwyther LP. The perspective of the person with Alzheimer disease: which outcomes matter in early to middle stages of dementia? Alz Dis Assoc Disord 1997; 11 Suppl. 6: 18–24

    Google Scholar 

  31. Wood S, Cummings JL. Measuring outcomes in Alzheimer’s disease research: assessment of the effectiveness of interventions. Dis Manage Health Outcomes 1999; 5 (1): 1–12

    Article  Google Scholar 

  32. Kane RL. Which outcomes matter in Alzheimer disease and who should define them? Alz Dis Assoc Disord 1997; 11 Suppl. 6: 12–7

    Google Scholar 

  33. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease: results from a multinational trial. Dementia Geriatr Cogn Disord 1999; 10: 237–44

    Article  CAS  Google Scholar 

  34. Doody RS, Pratt RD, Perdomo CA. Clinical benefits of donepezil: results from a long term phase III extension trial [abstract]. Neurology 1999 Apr; 52 Suppl. 2: A174

    Google Scholar 

  35. Pratt RD, Geldmacher D, Perdomo CA. An evaluation of the long term efficacy of donepezil in patients from a phase III clinical extension trial [abstract]. Neurology 1999 Apr; 52 Suppl. 2: A481–2

    Google Scholar 

  36. Friedhoff LT, Rogers SL. Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer’s disease [abstract]. Eur Neuropsychopharmacol 1997 Sep; 7 Suppl. 2: S246

    Google Scholar 

  37. Winblad B, Hill S, Beermann B, et al. Issues in the economic evaluation of treatment for dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 3: 39–45

    PubMed  Google Scholar 

  38. Kaufer D, Catt K, Pollock B, et al. Assessing the effects of donepezil in Alzheimer’s patients and its impact on caregivers [abstract]. J Am Geriatr Soc 1998 Sep; 46: S66

    Google Scholar 

  39. McRae T, Relkin N, Knopman D. A large-scale, open-label trial of donepezil in the treatment of Alzheimer’s disease [abstract]. Neurology 1998 Apr; 50 Suppl. 4: A90

    Google Scholar 

  40. Post S, Whitehouse PJ. Emerging antidementia drugs: a preliminary ethical view. J Am Geriatr Soc 1998 Jun; 46: 784–7

    PubMed  CAS  Google Scholar 

  41. Geldmacher DS. Donepezil (Aricept) therapy for Alzheimer’s disease. Compr Ther 1997 Jul; 23: 492–3

    PubMed  CAS  Google Scholar 

  42. Rogers SL, Friedhoff LT. Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer’s disease [abstract]. Eur Neuropsychopharmacol 1997 Sep; 7 Suppl. 2: 251

    Google Scholar 

  43. Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 2: issues in assessing drug effects. Pharmacoeconomics 1998 Dec; 14: 613–27

    Article  PubMed  CAS  Google Scholar 

  44. Donepezil update. Drug Ther Bull 1998 Aug; 36: 60–1

    Article  Google Scholar 

  45. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther 1998 Jul-Aug; 20: 838–50

    CAS  Google Scholar 

  46. Max W. The cost of Alzheimer’s disease: will drug treatment ease the burden? Pharmacoeconomics 1996 Jan; 9: 5–10

    Article  PubMed  CAS  Google Scholar 

  47. Max W. Drug treatments for Alzheimer’s disease: shifting the burden of care. CNS Drugs 1999 May; 11 (5): 363–72

    Article  Google Scholar 

  48. Busschbach JJV, Brouwer WBF, van der Donk A, et al. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer’s disease. Pharmacoeconomics 1998 Jan; 13 (1 Pt 1): 21–34

    Article  PubMed  CAS  Google Scholar 

  49. O’Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 1999; 47 (5): 570–8

    PubMed  Google Scholar 

  50. Lanctôt KL, Risebrough N, Oh PI. Factors affecting the economic attractiveness of cognitive enhancers in Alzheimer’s disease [abstract]. J Clin Pharmacol 1998 Sep; 38: 870

    Google Scholar 

  51. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 1999; 52 (6): 1138–45

    Article  PubMed  CAS  Google Scholar 

  52. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezil. Int J Geriatr Psychiatry 1998; 13: 445–53

    Article  PubMed  CAS  Google Scholar 

  53. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility preference functions for a comprehensive health status classification system: Health Utilitites Index Mark 2. Med Care 1996; 34: 707–22

    Article  Google Scholar 

  54. Neumann PJ, Hermann RC, Weinstein MC. Measuring QALYs in dementia. In: Wimo A, Karlsson G, Jönsson B, editors. Health economics in dementia. Chichester: Wiley, 1998

    Google Scholar 

  55. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992 Feb 15; 146 (4): 473–81

    CAS  Google Scholar 

  56. Milne RJ. Pharmacoeconomic models in disease management: a guide for the novice or perplexed. Dis Manage Health Outcomes 1998 Sep; 4 (3): 119–34

    Article  Google Scholar 

  57. Neumann PJ, Hermann RC, Berenbaum PA, et al. Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer’s disease. Psychiatr Serv 1997 Nov; 48: 1440–4

    PubMed  CAS  Google Scholar 

  58. Wimo A, Karlsson G, Jönsson B, et al., editors. Health economics of dementia. Chichester: Wiley, 1998

    Google Scholar 

  59. Robert P, Lebert F, Goni S, et al. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer’s disease. Presented at the 152nd Annual Meeting of the American Psychiatric Association; 15–20 May 1999; Washington DC, USA

    Google Scholar 

  60. Hollister L, Gruber N. Drug treatment of Alzheimer’s disease: effects on caregiver burden and patient quality of life. Drugs Aging 1996 Jan; 8: 47–55

    Article  PubMed  CAS  Google Scholar 

  61. 61. Standing Medical Advisory Committee. The use of donepezil for Alzheimer’s disease [online]. Department of Health; 1998 May 1. Available from: URL: http://www.doh.gov.UK/-donep.htm [accessed 1999 Feb 10]

  62. Knopman D, Schneider L, Davis K, et al. Long term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996 Jul; 47: 166–77

    Article  PubMed  CAS  Google Scholar 

  63. Wimo A, Karlsson G, Nordberg A. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alz Dis Assoc Disord 1997 Dec; 11: 191–200

    CAS  Google Scholar 

  64. Whitehouse PJ. Cholinesterase inhibitors in Alzheimer’s disease: are they worth the cost? CNS Drugs 1999 Mar; 11 (3): 167–73

    Article  Google Scholar 

  65. Whitehouse PJ, Winblad B, Shostak D, et al. First international pharmacoeconomic conference on Alzheimer’s disease: report and summary. Alz Dis Assoc Disord 1998; 12 (4): 266–80

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Rachel H. Foster & Greg L. Plosker

Authors
  1. Rachel H. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel H. Foster.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foster, R.H., Plosker, G.L. Donepezil. Pharmacoeconomics 16, 99–114 (1999). https://doi.org/10.2165/00019053-199916010-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199916010-00009

Keywords

Search

Navigation